The pretreatment neutrophil/lymphocyte ratio is associated with all-cause mortality in black and white patients with non-metastatic breast cancer

Joseph Rimando, Jeff Campbell, Jae Hee Kim, Shou-Ching Tang, Sangmi Kim

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The pretreatment neutrophil/lymphocyte ratio (NLR), derived from differential white blood cell counts, has been previously associated with poor prognosis in breast cancer. Little data exist, however, concerning this association in Black patients, who are known to have lower neutrophil counts than other racial groups. We conducted a retrospective cohort study of 236 Black and 225 non-Hispanic White breast cancer patients treated at a single institution. Neutrophil and lymphocyte counts were obtained from electronic medical records. Univariate and multivariate Cox regression models were used to determine hazard ratios (HRs) and 95% confidence intervals (95% CIs) of all-cause mortality and breast cancer-specific mortality in relation to pretreatment NLR. Overall, there were no associations between an elevated pretreatment NLR (NLR ≥ 3.7) and all-cause or breast cancer-specific mortality. Among patients without metastasis at the time of diagnosis, an elevated pretreatment NLR was independently associated with all-cause mortality, with a multivariable HR of 2.31 (95% CI: 1.10-4.86). Black patients had significantly lower NLR values than White patients, but there was no evidence suggesting racial heterogeneity of the prognostic utility of NLR. Pretreatment NLR was an independent predictor of all-cause mortality but not breast cancer-specific mortality in non-metastatic breast cancer patients.

Original languageEnglish (US)
Article number81
JournalFrontiers in Oncology
Volume6
Issue numberMAR
DOIs
StatePublished - Jan 1 2016

Fingerprint

Neutrophils
Lymphocytes
Breast Neoplasms
Mortality
hydroquinone
Confidence Intervals
Electronic Health Records
Lymphocyte Count
Leukocyte Count
Proportional Hazards Models
Cohort Studies
Retrospective Studies
Neoplasm Metastasis

Keywords

  • All-cause mortality
  • Black patients
  • Breast cancer
  • Neutrophil/lymphocyte ratio
  • White patients

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

The pretreatment neutrophil/lymphocyte ratio is associated with all-cause mortality in black and white patients with non-metastatic breast cancer. / Rimando, Joseph; Campbell, Jeff; Kim, Jae Hee; Tang, Shou-Ching; Kim, Sangmi.

In: Frontiers in Oncology, Vol. 6, No. MAR, 81, 01.01.2016.

Research output: Contribution to journalArticle

Rimando, Joseph ; Campbell, Jeff ; Kim, Jae Hee ; Tang, Shou-Ching ; Kim, Sangmi. / The pretreatment neutrophil/lymphocyte ratio is associated with all-cause mortality in black and white patients with non-metastatic breast cancer. In: Frontiers in Oncology. 2016 ; Vol. 6, No. MAR.
@article{40a2307909fa403191f0a66c6006cfaa,
title = "The pretreatment neutrophil/lymphocyte ratio is associated with all-cause mortality in black and white patients with non-metastatic breast cancer",
abstract = "The pretreatment neutrophil/lymphocyte ratio (NLR), derived from differential white blood cell counts, has been previously associated with poor prognosis in breast cancer. Little data exist, however, concerning this association in Black patients, who are known to have lower neutrophil counts than other racial groups. We conducted a retrospective cohort study of 236 Black and 225 non-Hispanic White breast cancer patients treated at a single institution. Neutrophil and lymphocyte counts were obtained from electronic medical records. Univariate and multivariate Cox regression models were used to determine hazard ratios (HRs) and 95{\%} confidence intervals (95{\%} CIs) of all-cause mortality and breast cancer-specific mortality in relation to pretreatment NLR. Overall, there were no associations between an elevated pretreatment NLR (NLR ≥ 3.7) and all-cause or breast cancer-specific mortality. Among patients without metastasis at the time of diagnosis, an elevated pretreatment NLR was independently associated with all-cause mortality, with a multivariable HR of 2.31 (95{\%} CI: 1.10-4.86). Black patients had significantly lower NLR values than White patients, but there was no evidence suggesting racial heterogeneity of the prognostic utility of NLR. Pretreatment NLR was an independent predictor of all-cause mortality but not breast cancer-specific mortality in non-metastatic breast cancer patients.",
keywords = "All-cause mortality, Black patients, Breast cancer, Neutrophil/lymphocyte ratio, White patients",
author = "Joseph Rimando and Jeff Campbell and Kim, {Jae Hee} and Shou-Ching Tang and Sangmi Kim",
year = "2016",
month = "1",
day = "1",
doi = "10.3389/fonc.2016.00081",
language = "English (US)",
volume = "6",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",
number = "MAR",

}

TY - JOUR

T1 - The pretreatment neutrophil/lymphocyte ratio is associated with all-cause mortality in black and white patients with non-metastatic breast cancer

AU - Rimando, Joseph

AU - Campbell, Jeff

AU - Kim, Jae Hee

AU - Tang, Shou-Ching

AU - Kim, Sangmi

PY - 2016/1/1

Y1 - 2016/1/1

N2 - The pretreatment neutrophil/lymphocyte ratio (NLR), derived from differential white blood cell counts, has been previously associated with poor prognosis in breast cancer. Little data exist, however, concerning this association in Black patients, who are known to have lower neutrophil counts than other racial groups. We conducted a retrospective cohort study of 236 Black and 225 non-Hispanic White breast cancer patients treated at a single institution. Neutrophil and lymphocyte counts were obtained from electronic medical records. Univariate and multivariate Cox regression models were used to determine hazard ratios (HRs) and 95% confidence intervals (95% CIs) of all-cause mortality and breast cancer-specific mortality in relation to pretreatment NLR. Overall, there were no associations between an elevated pretreatment NLR (NLR ≥ 3.7) and all-cause or breast cancer-specific mortality. Among patients without metastasis at the time of diagnosis, an elevated pretreatment NLR was independently associated with all-cause mortality, with a multivariable HR of 2.31 (95% CI: 1.10-4.86). Black patients had significantly lower NLR values than White patients, but there was no evidence suggesting racial heterogeneity of the prognostic utility of NLR. Pretreatment NLR was an independent predictor of all-cause mortality but not breast cancer-specific mortality in non-metastatic breast cancer patients.

AB - The pretreatment neutrophil/lymphocyte ratio (NLR), derived from differential white blood cell counts, has been previously associated with poor prognosis in breast cancer. Little data exist, however, concerning this association in Black patients, who are known to have lower neutrophil counts than other racial groups. We conducted a retrospective cohort study of 236 Black and 225 non-Hispanic White breast cancer patients treated at a single institution. Neutrophil and lymphocyte counts were obtained from electronic medical records. Univariate and multivariate Cox regression models were used to determine hazard ratios (HRs) and 95% confidence intervals (95% CIs) of all-cause mortality and breast cancer-specific mortality in relation to pretreatment NLR. Overall, there were no associations between an elevated pretreatment NLR (NLR ≥ 3.7) and all-cause or breast cancer-specific mortality. Among patients without metastasis at the time of diagnosis, an elevated pretreatment NLR was independently associated with all-cause mortality, with a multivariable HR of 2.31 (95% CI: 1.10-4.86). Black patients had significantly lower NLR values than White patients, but there was no evidence suggesting racial heterogeneity of the prognostic utility of NLR. Pretreatment NLR was an independent predictor of all-cause mortality but not breast cancer-specific mortality in non-metastatic breast cancer patients.

KW - All-cause mortality

KW - Black patients

KW - Breast cancer

KW - Neutrophil/lymphocyte ratio

KW - White patients

UR - http://www.scopus.com/inward/record.url?scp=84964553537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964553537&partnerID=8YFLogxK

U2 - 10.3389/fonc.2016.00081

DO - 10.3389/fonc.2016.00081

M3 - Article

VL - 6

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

IS - MAR

M1 - 81

ER -